TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
ASND

Ascendis Pharma AS

Healthcare · Biotechnology

230.10$ +2.0% vs. previous close Closing price · As of: Sep 28, 2026

Statements

Income Statement

Ascendis Pharma AS (ASND) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 345 million EUR. Tick rows to compare them in a chart.

All figures in millions of EUR.

Tick rows to compare them in a chart (up to 4)

Income Statement ASND
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
48 138 96 36 58 174 101 158 214 245 251 345 1,054
7.4 19 7.6 11 11 14 18 31 22 27 22 32 103
41 118 88 25 47 160 83 127 191 218 229 313 951
111 91 71 83 74 79 87 72 67 75 58 75 274
63 64 72 72 68 79 96 106 112 135 145 172 564
175 155 137 158 143 160 188 180 180 208 204 249 841
-134 -37 -49 -133 -97 0.4 -104 -53 11 9.8 25 63 109
25 69 77 20 25 57 45 33 20 61 68 14 164
-162 -81 -129 -109 -98 -37 -94 -35 -57 -26 -49 234 101
0.6 5.8 2.5 0.2 1.0 1.1 1.1 3.8 3.6 6.8 -689 24 -655
-162 -87 -131 -109 -99 -38 -95 -39 -61 -33 640 210 756
-132 -68 -47 -88 -71 -38 -44 2.3 -53 40 24 68 78

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?